Since the introduction of ipilimumab (an anti-CTLA-4 antibody) in 2010, ICI therapies have become widely used for the treatment of patients with solid tumors and, more recently, with advanced-stage HCC [18,19,20]. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.